Members of Seanad Éireann (the Senate), the upper house of the Oireachtas (the Irish legislature) made tributes in honour of former Senator, Dr. Edward Haughey, at their debate on 1 October 2014.
Norbrook® Laboratories Ltd was founded by the current Chairman and CEO, Lord Ballyedmond, in the late 1960's, when he pioneered contract manufacturing of pharmaceuticals in the UK. Since then Norbrook has grown to be a worldwide leader in veterinary finished dose form products, medical finished dose form products and bulk pharmaceutical synthesis, making them a leader in the world in the production of pharmaceutical raw materials.
Most recently the company launched Closamectin Pour On, which has revolutionised the treatment of large animals for parasites (for more information about Closamectin visit www.closamectin.com). This is the only product available in Europe for treating parasites including fluke, by pouring it on the back of the animal. Norbrook has a large pipeline of new products which will be coming to the world market from December of this year, which we believe will put Norbrook in the forefront of novel product development in the next decade and beyond.
History of Norbrook
|1969||Norbrook was founded.|
|1970||Norbrook began manufacture of veterinary pharmaceuticals|
|1974||The first Norbrook patent was granted|
|1978||Norbrook expanded into Africa|
|1980||Norbrook expanded into Japan|
|1987||Norbrook received its first Queens Award for Export|
|1990||Norbrook expanded into Eastern Europe|
|1994||Norbrook announced its £38m expansion programme|
|1996||Norbrook expanded into People’s Republic of China|
|1998||Norbrook expanded into medical and raw material pharmaceutical production|
|2000||Norbrook expanded into Australia and New Zealand|
|2001||Norbrook launched their first major product for cats and dogs globally|
|2002||Norbrook received the Queens Award for Export Achievement for the fourth time|
|2005||Norbrook Laboratories announced Czech acquisition|
|2006||Norbrook’s novel combination of Ivermectin and Closantel received its license by the UK regulatory authorities.
Norbrook invested £30m in a molecular development facility
|2007||Norbrook announced an £83m investment in R&D|
|2009||Norbrook launched Closamectin Pour On for cattle|
|2010||Norbrook launched Closamectin Injection for sheep|
|2011||Norbrook received the Queens Award for Enterprise|